Katerina Stavrianidis is an associate in Goodwin’s Technology & Life Sciences group and a member of the firm’s Intellectual Property Transactions and Strategies practice. She joined Goodwin in 2020. Katerina represents public and private life sciences companies in collaboration, licensing, manufacturing, supply and distribution arrangements, research and development agreements, M&A, financing, and other intellectual property and strategic transactions.
REPRESENTATIVE MATTERS
- Eidos Therapeutics in its exclusive license agreement with Bayer to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in Europe
- Entrada Therapeutics in its global collaboration with Vertex on intracellular Endosomal Escape Vehicle (EEV™) therapeutics for DM1
- Akili Interactive Labs in its business combination with Social Capital Suvretta Holdings Corp. I
- Entrada Therapeutics in its initial public offering
- Chain Bridge in its SPAC initial public offering
- Big Sky Growth Partners in its SPAC initial public offering
- The underwriters in Bright Health Group’s initial public offering
Professional Experience
Katerina has undertaken a client secondment at Compass Therapeutics.
Prior to joining Goodwin, Katerina was an associate at Proskauer Rose, where her practice focused on patent prosecution and litigation.
Prior to attending law school, Katerina worked as a mechanical engineer in the fire protection industry, where she handled projects involving new and existing product development, manufacturing capabilities, quality control, and agency compliance for water-based fire protections products.
Credentials
Education
JDConcentration in Intellectual Property and Innovation and Business and Commercial Law2019
Northeastern University School of Law
MSSystems Engineering2016
University of Rhode Island
BSIndustrial and Systems Engineering2012
University of Rhode Island
Admissions
Bars
- Massachusetts